Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset

TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating today.

Yaron Werber has given his Buy rating due to a combination of factors that highlight Stoke Therapeutics’ promising future. The company has reported significantly higher revenue than expected, primarily driven by a substantial upfront milestone from their partnership with Biogen. This collaboration not only provides financial support but also strategic advantages, as it helps Stoke leverage Biogen’s infrastructure for commercialization efforts.
Furthermore, the potential of Stoke’s lead asset, zorevunersen, in the Dravet market is substantial. The market is large, with a high anticipated penetration due to the drug’s disease-modifying efficacy and minimal competition. The premium pricing and long treatment durations further enhance its commercial prospects. With a strong cash position and a validated asset ready for Phase 3 trials, Stoke Therapeutics presents a compelling investment opportunity, justifying the Buy rating.

In another report released today, Needham also maintained a Buy rating on the stock with a $22.00 price target.